Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix

BOULDER - Fresh Tracks Therapeutics, Inc. , a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the...

Related Keywords

Japan ,South Korea ,United States ,Andrew Sklawer ,Fresh Tracks Therapeutics Inc ,Botanix Pharmaceuticals Limited ,Botanix Sb Inc ,Company Or Fresh Tracks Nasdaq ,Nasdaq ,Tracks Therapeutics ,Fresh Tracks ,Asset Purchase Agreement ,Pharmaceuticals Limited ,Chief Executive Officer ,Current Report ,Fresh Track ,Securities Litigation Reform Act ,News Publishing ,Markets ,